Instrument Inactif

Autres langues Merrimack Pharmaceuticals Inc Nasdaq

Actions

US5903281005

Recherche biotechnologique et médicale

Autres langues

21/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P Global BMI Index
21/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from S&P TMI Index
17/05/24	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) dropped from NASDAQ Composite Index
15/05/24	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
13/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock
10/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
09/05/24	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Payable on or About May 17, 2024
09/05/24	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
30/04/24	Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
27/03/24	Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
27/03/24	Merrimack Receives $225 Million Milestone Payment from Ipsen
07/03/24	Merrimack Reports Full Year 2023 Financial Results
07/03/24	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
14/02/24	Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma
14/02/24	Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen
13/02/24	Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval
13/02/24	Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
16/11/23	Merrimack Pharmaceuticals Insider Bought Shares Worth $627,125, According to a Recent SEC Filing
02/11/23	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
02/11/23	Merrimack Reports Third Quarter 2023 Financial Results
18/09/23	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to S&P Global BMI Index
09/08/23	Insider Buy: Merrimack Pharmaceuticals
03/08/23	Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
03/08/23	Merrimack Reports Second Quarter 2023 Financial Results
23/06/23	Merrimack Pharmaceuticals, Inc.(NasdaqGM:MACK) added to Russell 3000E Growth Index